Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Lung Diseases

肺生物学和肺部疾病中的干细胞、细胞疗法和生物工程

基本信息

批准号：
10753310
负责人：
Amy Leanne Ryan
金额：
$ 3.5万
依托单位：
UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-07-15 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10753310
关键词：
3-Dimensional Address American Animal Model Area Award Basic Science Biology Biomedical Engineering Blinded Career Mobility Cell Therapy Cells Chest Clinic Clinical Clinical Research Communication Communities Critical Illness Cystic Fibrosis Data Development Disease European Event Faculty Fostering Foundations Funding Funding Agency Funding Opportunities Future Goals Grant Growth Guidelines Hybrids Immune response Injury International Journals Lung Lung diseases Mentors Molecular Motivation National Heart, Lung, and Blood Institute Natural regeneration Oral Participant Pathologic Persons Physiology Postdoctoral Fellow Pre-Clinical Model Publishing Pulmonary Fibrosis Recommendation Regulation Research Research Personnel Research Support Respiratory Disease Role Science Series Societies Stem Cell Research Students Therapeutic Time Tissue Engineering Training Translating Translational Research Transplantation Travel Underrepresented Minority Underrepresented Populations United States National Aeronautics and Space Administration United States National Institutes of Health Universities Vermont Woman Women&apos s Group airway regeneration career development combat design graduate student immunoregulation induced pluripotent stem cell innovation insight lung development lung injury lung regeneration meetings phrases postdoctoral investigator posters programs repaired respiratory scaffold scientific organization skill acquisition stem cells symposium technology/technique translational study

项目摘要

Project Summary Repair and regeneration of a diseased lung with stem cells or bioengineered tissues are exciting potential therapeutic approaches for a variety of lung diseases and critical illnesses. Over the past decade, increasing evidence in preclinical models suggests that cells which are not normally resident in the lung can be utilized to modulate immune responses after injury, but there have been challenges in translating these promising findings to the clinic. In parallel, there has been a surge in bioengineering studies investigating use of artificial and acellular lung matrices as scaffolds for three-dimensional lung or airway regeneration, with some recent attempts of transplantation in large animal models. The combination of these studies with those utilizing stem cells, induced pluripotent stem cell derivatives, and/or cell therapies is a promising and rapidly developing research area. These studies have been further paralleled by significant increases in understanding the molecular and cellular events by which endogenous lung stem and/or progenitor cells arise and differentiate during lung development and in normal and pathologic repair and remodeling after lung injury. We have held nine previous biennial conferences at the University of Vermont from 2005 through 2021. The previous conferences, and the planned 2023 conference, have filled an important niche in the rapidly moving fields of stem cells, cell therapies, lung biology, and bioengineering. Conducted in the style of the Gordon Conferences, there are no other comparable meetings that allow the depth and breadth of discussion, deliberation, and connection that occurs. Importantly, in addition to participation by leading figures in lung biology and disease, we have regularly attracted prominent (non-lung) stem cell experts to give featured plenary presentations, bringing innovation into the field. This is an important feature of the program and is a continuing mark of the stature and importance of the conference. These conferences have been highly successful and have resulted in a series of guidelines for basic, translational, and clinical research to be utilized by both investigators and funding agencies. As studies on stem cell and cell therapies for lung diseases continues to move at a rapid pace and the field explores how to best translate these approaches, we propose to again convene the relevant investigators as well as representatives from the NHLBI, FDA, and leading non-profit respiratory disease foundations to discuss current issues. As always, junior investigators, trainees, and investigators from underrepresented groups will be prioritized for inclusion in conference organization, oral presentations, chairing activities, discussions, and poster sessions. Trainees will be able to compete for an increased number of travel awards based on blinded review of submitted abstracts. The conference is planned as an in-person event with a hybrid online option to increase participation of underrepresented minorities and overseas students in July 2023 at the University of Vermont. We anticipate that this conference will continue to foster extensive discussion and debate and will significantly guide directions in basic, translational, and clinical research of stem cells, cell therapies, and bioengineering approaches for lung diseases.

项目摘要用干细胞或生物工程组织的肺修复和再生是令人兴奋的潜力各种肺部疾病和重症疾病的治疗方法。在过去的十年中，增加临床前模型中的证据表明，通常在肺中居民的细胞可用于受伤后调节免疫反应，但是在翻译这些有前途的发现方面存在挑战去诊所。同时，生物工程研究的激增，调查了人工和细胞肺矩阵作为三维肺或气道再生的支架，最近尝试大型动物模型中的移植。这些研究与利用干细胞的研究的结合，诱导多能干细胞衍生物和/或细胞疗法是一项有希望且迅速发展的研究区域。这些研究在理解分子和内源性肺茎和/或祖细胞的细胞事件在肺中出现并分化肺损伤后发育，正常和病理修复和重塑。我们以前曾持有九个从2005年到2021年，在佛蒙特大学举行了两年一次的会议。计划的2023会议填补了干细胞，细胞疗法快速移动的领域的重要利基市场肺部生物学和生物工程。以戈登会议的风格进行的可比较的会议，允许发生讨论，审议和联系的深度和广度。重要的是，除了由领先数字参与肺部生物学和疾病之外，我们还定期吸引著名的（非肺部）干细胞专家提供特色全体演讲，从而将创新带入了领域。这是该程序的重要特征，并且是持续的标志会议。这些会议非常成功，并为基本的一系列准则，转化和临床研究将由研究人员和资助机构使用。作为茎的研究肺部疾病的细胞和细胞疗法继续以快速的速度移动，该领域探索了如何最好的翻译这些方法，我们建议再次召集相关的研究人员以及代表来自NHLBI，FDA和领先的非营利呼吸道疾病基础，讨论当前问题。作为始终将来自代表性不足的团体的初级调查人员，学员和调查员优先考虑纳入会议组织，口头演讲，主席活动，讨论和海报会议。学员将能够根据提交的盲目评论来争夺增加的旅行奖项摘要。该会议计划是一个面对面的活动，并提供混合在线选项，以增加参与 2023年7月在佛蒙特大学的代表性少数群体和海外学生的成员。我们期待这次会议将继续促进广泛的讨论和辩论，并将大力指导指示。在干细胞，细胞疗法和生物工程方法的基本，翻译和临床研究中疾病。